We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Expressed in all
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Antibody staining consistent with RNA expression data.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
All malignant tissues exhibited strong nuclear immunoreactivity.
Malignancies displayed strong nuclear and cytoplasmic positivity.
GENE INFORMATIONi
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
Gene name
MDM2 (HGNC Symbol)
Synonyms
HDM2, MGC5370
Description
MDM2 proto-oncogene (HGNC Symbol)
Entrez gene summary
This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
Enzymes ENZYME proteins Transferases Predicted intracellular proteins Cancer-related genes Candidate cancer biomarkers COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Disease related genes Potential drug targets Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0001568 [blood vessel development] GO:0001974 [blood vessel remodeling] GO:0002027 [regulation of heart rate] GO:0002039 [p53 binding] GO:0003170 [heart valve development] GO:0003181 [atrioventricular valve morphogenesis] GO:0003203 [endocardial cushion morphogenesis] GO:0003281 [ventricular septum development] GO:0003283 [atrial septum development] GO:0004842 [ubiquitin-protein transferase activity] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005730 [nucleolus] GO:0005737 [cytoplasm] GO:0005829 [cytosol] GO:0005886 [plasma membrane] GO:0006461 [protein complex assembly] GO:0006977 [DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest] GO:0007089 [traversing start control point of mitotic cell cycle] GO:0007507 [heart development] GO:0008270 [zinc ion binding] GO:0008284 [positive regulation of cell proliferation] GO:0009636 [response to toxic substance] GO:0010039 [response to iron ion] GO:0010468 [regulation of gene expression] GO:0010628 [positive regulation of gene expression] GO:0010629 [negative regulation of gene expression] GO:0010955 [negative regulation of protein processing] GO:0010977 [negative regulation of neuron projection development] GO:0016032 [viral process] GO:0016567 [protein ubiquitination] GO:0016579 [protein deubiquitination] GO:0016604 [nuclear body] GO:0016740 [transferase activity] GO:0016874 [ligase activity] GO:0016925 [protein sumoylation] GO:0018205 [peptidyl-lysine modification] GO:0019789 [SUMO transferase activity] GO:0019899 [enzyme binding] GO:0030666 [endocytic vesicle membrane] GO:0031625 [ubiquitin protein ligase binding] GO:0031648 [protein destabilization] GO:0032026 [response to magnesium ion] GO:0032436 [positive regulation of proteasomal ubiquitin-dependent protein catabolic process] GO:0034504 [protein localization to nucleus] GO:0036369 [transcription factor catabolic process] GO:0042176 [regulation of protein catabolic process] GO:0042220 [response to cocaine] GO:0042493 [response to drug] GO:0042787 [protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:0042802 [identical protein binding] GO:0042975 [peroxisome proliferator activated receptor binding] GO:0043066 [negative regulation of apoptotic process] GO:0043154 [negative regulation of cysteine-type endopeptidase activity involved in apoptotic process] GO:0043234 [protein complex] GO:0043278 [response to morphine] GO:0043518 [negative regulation of DNA damage response, signal transduction by p53 class mediator] GO:0045184 [establishment of protein localization] GO:0045202 [synapse] GO:0045472 [response to ether] GO:0045787 [positive regulation of cell cycle] GO:0045892 [negative regulation of transcription, DNA-templated] GO:0045931 [positive regulation of mitotic cell cycle] GO:0046677 [response to antibiotic] GO:0046827 [positive regulation of protein export from nucleus] GO:0046872 [metal ion binding] GO:0048545 [response to steroid hormone] GO:0051865 [protein autoubiquitination] GO:0060411 [cardiac septum morphogenesis] GO:0061630 [ubiquitin protein ligase activity] GO:0070301 [cellular response to hydrogen peroxide] GO:0071157 [negative regulation of cell cycle arrest] GO:0071236 [cellular response to antibiotic] GO:0071301 [cellular response to vitamin B1] GO:0071310 [cellular response to organic substance] GO:0071312 [cellular response to alkaloid] GO:0071363 [cellular response to growth factor stimulus] GO:0071375 [cellular response to peptide hormone stimulus] GO:0071391 [cellular response to estrogen stimulus] GO:0071407 [cellular response to organic cyclic compound] GO:0071456 [cellular response to hypoxia] GO:0071494 [cellular response to UV-C] GO:0097110 [scaffold protein binding] GO:1901796 [regulation of signal transduction by p53 class mediator] GO:1901797 [negative regulation of signal transduction by p53 class mediator] GO:1904404 [response to formaldehyde] GO:1904707 [positive regulation of vascular smooth muscle cell proliferation] GO:1904754 [positive regulation of vascular associated smooth muscle cell migration] GO:1990785 [response to water-immersion restraint stress]
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0005634 [nucleus] GO:0008270 [zinc ion binding] GO:0016567 [protein ubiquitination] GO:0043066 [negative regulation of apoptotic process] GO:0046872 [metal ion binding] GO:0071157 [negative regulation of cell cycle arrest]
Q9H4C5 [Direct mapping] E3 ubiquitin-protein ligase Mdm2; p53-binding protein
Show all
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0008270 [zinc ion binding] GO:0016567 [protein ubiquitination] GO:0046872 [metal ion binding]
Enzymes ENZYME proteins Transferases Predicted intracellular proteins Cancer-related genes Candidate cancer biomarkers COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Disease related genes Potential drug targets Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0002039 [p53 binding] GO:0004842 [ubiquitin-protein transferase activity] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005730 [nucleolus] GO:0005737 [cytoplasm] GO:0005829 [cytosol] GO:0005886 [plasma membrane] GO:0006461 [protein complex assembly] GO:0006977 [DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest] GO:0008270 [zinc ion binding] GO:0008284 [positive regulation of cell proliferation] GO:0016032 [viral process] GO:0016567 [protein ubiquitination] GO:0016579 [protein deubiquitination] GO:0016604 [nuclear body] GO:0016740 [transferase activity] GO:0016874 [ligase activity] GO:0016925 [protein sumoylation] GO:0018205 [peptidyl-lysine modification] GO:0019789 [SUMO transferase activity] GO:0019899 [enzyme binding] GO:0030666 [endocytic vesicle membrane] GO:0031625 [ubiquitin protein ligase binding] GO:0031648 [protein destabilization] GO:0032436 [positive regulation of proteasomal ubiquitin-dependent protein catabolic process] GO:0034504 [protein localization to nucleus] GO:0036369 [transcription factor catabolic process] GO:0042176 [regulation of protein catabolic process] GO:0042787 [protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:0042802 [identical protein binding] GO:0043066 [negative regulation of apoptotic process] GO:0043234 [protein complex] GO:0043518 [negative regulation of DNA damage response, signal transduction by p53 class mediator] GO:0045184 [establishment of protein localization] GO:0045892 [negative regulation of transcription, DNA-templated] GO:0045931 [positive regulation of mitotic cell cycle] GO:0046677 [response to antibiotic] GO:0046872 [metal ion binding] GO:0051865 [protein autoubiquitination] GO:0061630 [ubiquitin protein ligase activity] GO:0071157 [negative regulation of cell cycle arrest] GO:0071456 [cellular response to hypoxia] GO:1901796 [regulation of signal transduction by p53 class mediator] GO:1901797 [negative regulation of signal transduction by p53 class mediator]
Enzymes ENZYME proteins Transferases Predicted intracellular proteins Cancer-related genes Candidate cancer biomarkers COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Disease related genes Potential drug targets Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0002039 [p53 binding] GO:0004842 [ubiquitin-protein transferase activity] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005730 [nucleolus] GO:0005737 [cytoplasm] GO:0005829 [cytosol] GO:0005886 [plasma membrane] GO:0006461 [protein complex assembly] GO:0006977 [DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest] GO:0008270 [zinc ion binding] GO:0008284 [positive regulation of cell proliferation] GO:0016032 [viral process] GO:0016567 [protein ubiquitination] GO:0016579 [protein deubiquitination] GO:0016604 [nuclear body] GO:0016740 [transferase activity] GO:0016874 [ligase activity] GO:0016925 [protein sumoylation] GO:0018205 [peptidyl-lysine modification] GO:0019789 [SUMO transferase activity] GO:0019899 [enzyme binding] GO:0030666 [endocytic vesicle membrane] GO:0031625 [ubiquitin protein ligase binding] GO:0031648 [protein destabilization] GO:0032436 [positive regulation of proteasomal ubiquitin-dependent protein catabolic process] GO:0034504 [protein localization to nucleus] GO:0036369 [transcription factor catabolic process] GO:0042176 [regulation of protein catabolic process] GO:0042787 [protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:0042802 [identical protein binding] GO:0043066 [negative regulation of apoptotic process] GO:0043234 [protein complex] GO:0043518 [negative regulation of DNA damage response, signal transduction by p53 class mediator] GO:0045184 [establishment of protein localization] GO:0045892 [negative regulation of transcription, DNA-templated] GO:0045931 [positive regulation of mitotic cell cycle] GO:0046677 [response to antibiotic] GO:0046872 [metal ion binding] GO:0051865 [protein autoubiquitination] GO:0061630 [ubiquitin protein ligase activity] GO:0071157 [negative regulation of cell cycle arrest] GO:0071456 [cellular response to hypoxia] GO:1901796 [regulation of signal transduction by p53 class mediator] GO:1901797 [negative regulation of signal transduction by p53 class mediator]
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0008270 [zinc ion binding] GO:0016567 [protein ubiquitination] GO:0046872 [metal ion binding]
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005730 [nucleolus] GO:0016567 [protein ubiquitination] GO:0042787 [protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:0043066 [negative regulation of apoptotic process] GO:0071157 [negative regulation of cell cycle arrest]
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0008270 [zinc ion binding] GO:0016567 [protein ubiquitination]
Q9H4C3 [Direct mapping] E3 ubiquitin-protein ligase Mdm2; p53 binding protein
Show all
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0008270 [zinc ion binding] GO:0016567 [protein ubiquitination]
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0005634 [nucleus] GO:0016567 [protein ubiquitination] GO:0043066 [negative regulation of apoptotic process] GO:0071157 [negative regulation of cell cycle arrest]
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0016567 [protein ubiquitination]
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0016567 [protein ubiquitination]
Enzymes ENZYME proteins Transferases Predicted intracellular proteins Cancer-related genes Candidate cancer biomarkers COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Disease related genes Potential drug targets Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0002039 [p53 binding] GO:0004842 [ubiquitin-protein transferase activity] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005730 [nucleolus] GO:0005737 [cytoplasm] GO:0005829 [cytosol] GO:0005886 [plasma membrane] GO:0006461 [protein complex assembly] GO:0006977 [DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest] GO:0008270 [zinc ion binding] GO:0008284 [positive regulation of cell proliferation] GO:0016032 [viral process] GO:0016567 [protein ubiquitination] GO:0016579 [protein deubiquitination] GO:0016604 [nuclear body] GO:0016740 [transferase activity] GO:0016874 [ligase activity] GO:0016925 [protein sumoylation] GO:0018205 [peptidyl-lysine modification] GO:0019789 [SUMO transferase activity] GO:0019899 [enzyme binding] GO:0030666 [endocytic vesicle membrane] GO:0031625 [ubiquitin protein ligase binding] GO:0031648 [protein destabilization] GO:0032436 [positive regulation of proteasomal ubiquitin-dependent protein catabolic process] GO:0034504 [protein localization to nucleus] GO:0036369 [transcription factor catabolic process] GO:0042176 [regulation of protein catabolic process] GO:0042787 [protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:0042802 [identical protein binding] GO:0043066 [negative regulation of apoptotic process] GO:0043234 [protein complex] GO:0043518 [negative regulation of DNA damage response, signal transduction by p53 class mediator] GO:0045184 [establishment of protein localization] GO:0045892 [negative regulation of transcription, DNA-templated] GO:0045931 [positive regulation of mitotic cell cycle] GO:0046677 [response to antibiotic] GO:0046872 [metal ion binding] GO:0051865 [protein autoubiquitination] GO:0061630 [ubiquitin protein ligase activity] GO:0071157 [negative regulation of cell cycle arrest] GO:0071456 [cellular response to hypoxia] GO:1901796 [regulation of signal transduction by p53 class mediator] GO:1901797 [negative regulation of signal transduction by p53 class mediator]
J3KN53 [Direct mapping] E3 ubiquitin-protein ligase Mdm2; MDM2 protein
Show all
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0005634 [nucleus] GO:0008270 [zinc ion binding] GO:0016567 [protein ubiquitination] GO:0043066 [negative regulation of apoptotic process] GO:0046872 [metal ion binding] GO:0071157 [negative regulation of cell cycle arrest]
Q9H4C5 [Direct mapping] E3 ubiquitin-protein ligase Mdm2; p53-binding protein
Show all
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0008270 [zinc ion binding] GO:0016567 [protein ubiquitination] GO:0046872 [metal ion binding]
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0008270 [zinc ion binding] GO:0016567 [protein ubiquitination]
The Human Protein Atlas project is funded
MENU
